Burned by Palforzia, Nestlé retreats from its pharma experiment
The chocolate-to-vitamins giant discovers that launching a drug is hard. Should its biopharma partners be worried?
Pfizer hands another asset to Roivant
Does yesterday’s deal with Roivant mean the pharma giant is cooling on TL1A targeting? And what about Prometheus?
The problem with Her2-low testing
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
GSK’s “crown jewels” already look tarnished
As the company pulls Blenrep, questions about its future will only intensify.
